Physician profile
Tushar Ranchod
NPI 1316003304
$2,468.11
in general payments reported to CMS, 2019-2025
16 companies · $435 in 2025
The $435 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $60.17 · 2021: $78.71 · 2022: $321 · 2023: $300 · 2024: $844 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $578.12 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Genentech USA, INC. | $570.25 | 2019-2025 | Vabysmo |
| Astellas Pharma US INC | $352.28 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $228.12 | 2019-2023 | Iluvien |
| Biogen, INC. | $143.69 | 2022-2023 | |
| Genentech, INC. | $123.02 | 2019 | |
| Allergan, INC. | $103.61 | 2019-2020 | |
| Abbvie INC. | $81.25 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $60.22 | 2023 | Acthar |
| Regeneron Healthcare Solutions, INC. | $52.03 | 2021-2022 | |
| Optos, INC. | $36.99 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $36.55 | 2019 | |
| Apellis Pharmaceuticals, INC. | $34.51 | 2024 | Syfovre |
| Ocular Therapeutix, INC. | $29.99 | 2024 | Dextenza |
| Amgen INC. | $19.36 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $18.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tushar Ranchod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.